A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA2 activity

Clinica Chimica Acta

Volumn 411, Issue 3-4, 2010, Pages 190-197

  Benson, Marc A ^a   Schmalzer, Katherine M ^a   Frank, Dara W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

ExoU; PED6; Phospholipase A2; Pseudomonas aeruginosa

Indexed keywords

BACTERIAL PROTEIN; GLUTAMATE SODIUM; METHYL ARACHIDONYL FLUOROPHOSPHONATE; PHOSPHOLIPASE A1; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN EXOU; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EUKARYOTIC CELL; FLUORESCENCE ANALYSIS; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SENSIBILITY; SKIN DISEASE; VALIDATION STUDY;

ARACHIDONIC ACIDS; BACTERIAL PROTEINS; ENZYME ACTIVATION; ENZYME ASSAYS; ENZYME INHIBITORS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRACELLULAR SPACE; PHOSPHOLIPASES A2; PHOSPHONIC ACIDS; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; REPRODUCIBILITY OF RESULTS; SODIUM GLUTAMATE; SPECTROMETRY, FLUORESCENCE;

EUKARYOTA; PSEUDOMONAS AERUGINOSA;

EID: 72449131834     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.10.025     Document Type: Article

References (45)

1. Kang C.I., Kim S.H., Kim H.B., et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37 6 (2003 Sep 15) 745-751
2. Mutlu G.M., and Wunderink R.G. Severe pseudomonal infections. Curr Opin Crit Care 12 5 (2006 Oct) 458-463
3. Suarez C., Pena C., Tubau F., et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect 58 4 (2009 Apr) 285-290
4. Vance R.E., Rietsch A., and Mekalanos J.J. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 73 3 (2005 Mar) 1706-1713
5. Murray T.S., Egan M., and Kazmierczak B.I. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 19 1 (2007 Feb) 83-88
6. Franzetti F., Grassini A., Piazza M., et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 34 1 (2006 Feb) 9-16
7. Armour A.D., Shankowsky H.A., Swanson T., Lee J., and Tredget E.E. The impact of nosocomially-acquired resistant Pseudomonas aeruginosa infection in a burn unit. J Trauma 63 1 (2007 Jul) 164-171
8. Kohler T., Buckling A., and van Delden C. Cooperation and virulence of clinical Pseudomonas aeruginosa populations. Proc Natl Acad Sci USA 106 15 (Apr 14, 2009) 6339-6344
9. Rocha L.A., Vilela C.A., Cezario R.C., Almeida A.B., and Gontijo Filho P. Ventilator-associated pneumonia in an adult clinical-surgical intensive care unit of a Brazilian university hospital: incidence, risk factors, etiology, and antibiotic resistance. Braz J Infect Dis 12 1 (Feb 2008) 80-85
10. Maschmeyer G., and Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 19 12 (Dec 2000) 915-925
11. Schmiel D.H., and Miller V.L. Bacterial phospholipases and pathogenesis. Microbes Infect 1 13 (Nov 1999) 1103-1112
12. Sitkiewicz I., Stockbauer K.E., and Musser J.M. Secreted bacterial phospholipase A2 enzymes: better living through phospholipolysis. Trends Microbiol 15 2 (Feb 2007) 63-69
13. Geny B., and Popoff M.R. Bacterial protein toxins and lipids: role in toxin targeting and activity. Biol Cell 98 11 (Nov 2006) 633-651
14. Schmiel D.H., Wagar E., Karamanou L., Weeks D., and Miller V.L. Phospholipase A of Yersinia enterocolitica contributes to pathogenesis in a mouse model. Infect Immun 66 8 (Aug 1998) 3941-3951
15. Roy-Burman A., Savel R.H., Racine S., et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183 12 (Jun 15, 2001) 1767-1774
16. Sato H., Frank D.W., Hillard C.J., et al. The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J 22 12 (Jun 16, 2003) 2959-2969
17. Phillips R.M., Six D.A., Dennis E.A., and Ghosh P. In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors. J Biol Chem 278 42 (Oct 17, 2003) 41,326-41,332
18. Sato H., and Frank D.W. ExoU is a potent intracellular phospholipase. Mol Microbiol 53 5 (Sep 2004) 1279-1290
19. Rabin S.D., Veesenmeyer J.L., Bieging K.T., and Hauser A.R. A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Infect Immun 74 5 (May 2006) 2552-2561
20. Sato H., Feix J.B., and Frank D.W. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Biochemistry 45 34 (Aug 29, 2006) 10,368-10,375
21. Sato H., Feix J.B., Hillard C.J., and Frank D.W. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. J Bacteriol 187 3 (Feb 2005) 1192-1195
22. Rabin S.D., and Hauser A.R. Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 73 1 (Jan 2005) 573-582
23. Vallis A.J., Finck-Barbancon V., Yahr T.L., and Frank D.W. Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells. Infect Immun 67 4 (Apr 1999) 2040-2044
24. Finck-Barbancon V., Goranson J., Zhu L., et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 25 3 (Aug 1997) 547-557
25. Yahr T.L., Barbieri J.T., and Frank D.W. Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa. J Bacteriol 178 5 (Mar 1996) 1412-1419
26. Vogel H.J., and Bonner D.M. Acetylornithinase of Escherichia coli: partial purification and some properties. J Biol Chem 218 1 (Jan 1956) 97-106
27. Liu P.V. Exotoxins of Pseudomonas aeruginosa. I. Factors that influence the production of exotoxin A. J Infect Dis 128 4 (Oct 1973) 506-513
28. Iglewski B.H., Sadoff J., Bjorn M.J., and Maxwell E.S. Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A. Proc Natl Acad Sci USA 75 7 (Jul 1978) 3211-3215
29. Callahan L.T. Pseudomonas aeruginosa exotoxin: purification by preparative polyacrylamide gel electrophoresis and the development of a highly specific antitoxin serum. Infect Immun 14 1 (Jul 1976) 55-61
30. Cajal Y., Berg O.G., and Jain M.K. Origins of delays in monolayer kinetics: phospholipase A2 paradigm. Biochemistry 43 28 (Jul 20, 2004) 9256-9264
31. Apitz-Castro R., Jain M.K., and De Haas G.H. Origin of the latency phase during the action of phospholipase A2 on unmodified phosphatidylcholine vesicles. Biochim Biophys Acta 688 2 (Jun 14, 1982) 349-356
32. Berg O.G., Rogers J., Yu B.Z., Yao J., Romsted L.S., and Jain M.K. Thermodynamic and kinetic basis of interfacial activation: resolution of binding and allosteric effects on pancreatic phospholipase A2 at zwitterionic interfaces. Biochemistry 36 47 (Nov 25, 1997) 14,512-14,530
33. Lee V.T., Pukatzki S., Sato H., et al. Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 75 3 (Mar 2007) 1089-1098
34. Stirling F.R., Cuzick A., Kelly S.M., Oxley D., and Evans T.J. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin. Cell Microbiol 8 8 (Aug 2006) 1294-1309
35. Tausk R.J., Karmiggelt J., Oudshoorn C., and Overbeek J.T. Physical chemical studies of short-chain lecithin homologues. I. Influence of the chain length of the fatty acid ester and of electrolytes on the critical micelle concentration. Biophys Chem 1 3 (Feb 1974) 175-183
36. Li Z., Mintzer E., and Bittman R. The critical micelle concentrations of lysophosphatidic acid and sphingosylphosphorylcholine. Chem Phys Lipids 130 2 (Jul 2004) 197-201
37. Schick M. Effect of electrolyte and urea on micelle formation. J Phys Chem 68 12 (1964) 3585-3592
38. Stigter D. Micelle formation by ionic surfactants. II. Specificity of head groups, micelle structure. J Phys Chem 78 24 (11/01, 1974) 2480-2485
39. Anacker E.W., and Ghose H.M. Counterions and micelle size. I. Light scattering by solutions of dodecyltrimethylammonium salts. J Phys Chem 67 8 (08/01, 1963) 1713-1716
40. Tatulian S.A. Effect of lipid phase transition on the binding of anions to dimyristoylphosphatidylcholine liposomes. Biochim Biophys Acta 736 2 (Dec 21, 1983) 189-195
41. Yu B.Z., Poi M.J., Ramagopal U.A., et al. Structural basis of the anionic interface preference and kcat* activation of pancreatic phospholipase A2. Biochemistry 39 40 (Oct 10, 2000) 12,312-12,323
42. Yu B.Z., Rogers J., Tsai M.D., Pidgeon C., and Jain M.K. Contributions of residues of pancreatic phospholipase A2 to interfacial binding, catalysis, and activation. Biochemistry 38 15 (Apr 13, 1999) 4875-4884
43. Rogers J., Yu B.Z., Tsai M.D., Berg O.G., and Jain M.K. Cationic residues 53 and 56 control the anion-induced interfacial k*cat activation of pancreatic phospholipase A2. Biochemistry 37 26 (Jun 30, 1998) 9549-9556
44. Reynolds L.J., Hughes L.L., Louis A.I., Kramer R.M., and Dennis E.A. Metal ion and salt effects on the phospholipase A2, lysophospholipase, and transacylase activities of human cytosolic phospholipase A2. Biochim Biophys Acta 1167 3 (Apr 23, 1993) 272-280
45. Rakhit R., Crow J.P., Lepock J.R., Kondejewski L.H., Cashman N.R., and Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 279 15 (Apr 9, 2004) 15,499-15,504